Quick Dispatch:
Your tirzepatide cardiovascular outcomes trial results july 2025 In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16% orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular outcomes trial results july 2025 In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16% ships.
Need Help?
Questions about tirzepatide cardiovascular outcomes trial results july 2025 In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular outcomes trial results july 2025 In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16% in your area.
Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)
22.45
Abstract 4361308: Tirzepatide Reduces the Risk of Major Adverse Cardiovascular Events: An Individual Participant Data Meta-analysis of Phase 3 Randomized Clinical Trials
27.21
Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide
20.83
Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes
27.71
Targeting the weight within: obesity pharmacotherapy in cardiovascular disease
24.12
Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT | Diabetes Therapy
26.09
Will tirzepatide or semaglutide prove effective in primary prevention of cardiovascular disease?
26.95
